Cabaletta Bio, Inc. (CABA): Operating Income
-$172.24M
Year ended 2025-12-31
-$185.52M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$172.24M | n/m | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | -$125.14M | n/m | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | -$74.66M | n/m | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | -$54.14M | n/m | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | -$46.31M | n/m | 2023-03-16, From 2021-01-01 |
| 2020-12-31 | -$33.83M | n/m | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | -$18.68M | n/m | 2021-03-16, From 2019-01-01 |
| 2018-12-31 | -$6.19M | n/a | 2020-03-30, From 2018-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | -$172.24M | n/m |
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | -$112.79M | n/m |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | -$48.95M | n/m |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | -$158.37M | n/m |
| Compugen Ltd (CGEN) | 2025-12-31 | $31.33M | n/m |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | -$148.34M | n/m |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | -$52.15M | n/m |
| ImageneBio, Inc. (IMA) | 2025-12-31 | -$48.45M | n/m |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | -$51.97M | n/m |
Compare CABA, AURA, SABS, STRO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗